t
ImmuPharma PLC noted Incanthera plc's announcement dated 04 June 2026. This announcement detailed a corporate update and Board changes at Incanthera plc. As part of these Board changes, Tim McCarthy stepped down as Executive Chairman of Incanthera.
RNS REACH: RELEASE 4 June 2026
ImmuPharma PLC
("ImmuPharma" or the "Company")
Incanthera plc - Corporate Update & Board Changes
ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes today's announcement by Incanthera plc, "Incanthera", regarding a corporate update and subsequent Board changes. As part of the Board changes, Tim McCarthy has stepped down as Executive Chairman of Incanthera: Link: https://incanthera.com/ news-media/.
Ends
|
ImmuPharma PLC (www.immupharma.co.uk.) |
|
|
Tim McCarthy, Chief Executive Officer and Chairman
|
|
|
Lisa Baderoon, Head of Investor Relations |
+ 44 (0) 7721 413496
|
|
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin
Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney
SI Capital (Joint Broker) Nick Emerson |
+44 (0) 203 368 8974
+44 (0) 203 650 3650
+44 (0) 1483 413500
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.